ArticleOncology letters2025
YTHDC2 inhibits HPV-positive cervical cancer growth by suppressing SLC7A11 in a ferroptosis-dependent manner.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The mCells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic infection with high-risk human papillomavirus (HPV) types increases the risk of developing cervical cancer (CC). Notably, these HPV types are implicated in ~70% of all CC cases. YTH N6-methyladenosine RNA-binding protein C2 (YTHDC2) is an N6-methyladenosine reader associated with several cancers, although its specific function in CC remains poorly understood. The present study aimed to elucidate new functions of YTHDC2 in HPV-positive CC cell proliferation and ferroptosis, mediated by pathways dependent on protein synthesis. A comparative analysis revealed reduced levels of YTHDC2 in HPV-positive CC samples and cell lines compared with those in HPV-negative samples. YTHDC2 overexpression diminished cell viability and proliferation, whereas silencing YTHDC2 enhanced these processes, according to Cell Counting Kit-8 and colony formation assays. Cells overexpressing YTHDC2 exhibited characteristics of ferroptosis, such as apoptosis, reactive oxygen species production and imbalances in several ferroptosis indicators, including solute carrier family 7 member 11 (SLC7A11). A bioluminescent assay using a firefly luciferase construct fused with the SLC7A11 5'-untranslated region (UTR) demonstrated a reduction in luminescence in cells exhibiting enhanced YTHDC2 expression. This indicated that YTHDC2 catalyzes translation initiation via deconvolution of the 5'-UTR of SLC7A11 mRNA. Alterations to the 5'-UTR led to increased luciferase activity. Furthermore, increased SLC7A11 levels mitigated the effects of YTHDC2 overexpression on proliferation and ferroptosis in CC cells. In conclusion, the results of the present study suggest that low expression of the RNA helicase YTHDC2 contributes to CC proliferation and inhibition of ferroptosis by promoting SLC7A11 translation in HPV-positive CC cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.